PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Lung cancer is the leading cause of cancer-related mortality not only in the United States but
also around the world. In North America, lung cancer has become more predominant among …

Background The optimal chemotherapy regimen administered currently with radiation in
patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multicenter …

Purpose In lung cancer, randomized trials assessing hyperfractionated or accelerated
radiotherapy seem to yield conflicting results regarding the effects on overall (OS) or …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

Importance The 2 most common chemotherapy regimens used concurrently with thoracic
radiation for patients with unresectable IIIA and IIIB non–small-cell lung cancer (NSCLC) are …

Stage III nonsmall cell lung cancer (NSCLC) comprises about one-third of NSCLC patients
and is very heterogeneous with varying and mostly poor prognosis. It is also called …

Purpose The optimum dose and fractionation in radiation therapy of curative intent for non-
small cell lung cancer remains uncertain. We undertook a published data meta-analysis of …

PURPOSE: This Phase III study was performed to determine whether twice-daily (bid)
radiotherapy (RT) resulted in better survival than once-daily (qd) RT for patients with limited …

Objective To develop evidence-based guidelines on best available treatment options for
patients with stage IIIB non-small cell lung cancer (NSCLC). Methods A review was …